Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
2016 · Journal of Hematology & Oncology · 15 citations
https://doi.org/10.1186/s13045-016-0241-x
L
Lu‐Hong Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
376
Citations
13
h-index
16
i10-index
Lu‐Hong Xu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Hematopoietic Stem Cell Transplantation & Hemoglobinopathies and Related Disorders & Acute Lymphoblastic Leukemia research. The author has an h-index of 13, co-authored 47 publications.
ORCID: 0000-0001-7898-7720Papers by this author
worksNUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients
2024 · BMC Pediatrics · 3 citations
https://doi.org/10.1186/s12887-024-05007-3
The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia
2024 · BMC Medical Genomics · 1 citations
https://doi.org/10.1186/s12920-024-01892-w
Alanyl-Glutamine Inhibits the Epithelial-Mesenchymal Transition of Airway Epithelial Cells in Asthmatic Mice via DPP4-SIRT1 Pathway
2024 · International Archives of Allergy and Immunology · 1 citations
https://doi.org/10.1159/000541681
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat